O	0	10	Randomized
O	11	21	controlled
O	22	27	trial
O	28	30	of
B-intervention	31	35	high
I-intervention	35	36	-
I-intervention	36	40	dose
O	41	47	versus
B-control	48	56	standard
I-control	56	57	-
I-control	57	61	dose
I-control	62	69	vitamin
I-control	70	72	D3
O	73	76	for
O	77	87	prevention
O	88	90	of
B-condition	91	100	aromatase
I-condition	101	110	inhibitor
I-condition	110	111	-
I-condition	111	118	induced
I-condition	119	129	arthralgia
O	129	130	.

O	131	135	Half
O	136	138	of
O	139	146	hormone
O	147	155	receptor
O	155	156	-
O	156	164	positive
O	165	166	(
O	166	168	HR
O	168	169	+
O	169	170	)
O	171	177	breast
O	178	184	cancer
O	185	193	patients
O	194	198	will
O	199	206	develop
O	207	212	joint
O	213	217	pain
O	217	218	,
O	219	225	termed
O	226	235	aromatase
O	236	245	inhibitor
O	245	246	-
O	246	253	induced
O	254	264	arthralgia
O	265	266	(
O	266	269	AIA
O	269	270	)
O	270	271	,
O	272	277	while
O	278	284	taking
O	285	294	aromatase
O	295	304	inhibitor
O	305	312	therapy
O	312	313	.

O	314	320	Though
O	321	326	there
O	327	329	is
O	330	332	no
O	333	344	universally
O	345	353	accepted
O	354	363	effective
O	364	373	treatment
O	374	377	for
O	378	381	AIA
O	381	382	,
O	383	388	there
O	389	392	has
O	393	397	been
O	398	402	some
O	403	411	evidence
O	412	414	to
O	415	422	support
O	423	427	high
O	427	428	-
O	428	432	dose
O	433	440	vitamin
O	441	442	D
O	443	445	as
O	446	447	a
O	448	457	treatment
O	457	458	.

O	459	461	We
O	462	472	randomized
B-eligibility	473	477	post
I-eligibility	477	478	-
I-eligibility	478	488	menopausal
I-eligibility	489	494	women
I-eligibility	495	498	who
I-eligibility	499	503	were
I-eligibility	504	513	beginning
I-eligibility	514	522	adjuvant
I-eligibility	523	525	AI
I-eligibility	526	533	therapy
O	534	536	to
O	537	544	receive
O	545	553	standard
O	553	554	-
O	554	558	dose
O	559	566	vitamin
O	567	569	D3
O	570	571	(
O	571	574	800
O	575	577	IU
O	578	583	daily
O	584	587	for
O	588	590	52
O	591	596	weeks
O	596	597	)
O	597	598	,
O	599	601	or
O	602	606	high
O	606	607	-
O	607	611	dose
O	612	619	vitamin
O	620	622	D3
O	623	624	(
O	624	626	50
O	626	627	,
O	627	630	000
O	631	633	IU
O	634	640	weekly
O	641	644	for
O	645	647	12
O	648	653	weeks
O	653	654	,
O	655	663	followed
O	664	666	by
O	667	671	2000
O	672	674	IU
O	675	680	daily
O	681	684	for
O	685	687	40
O	688	693	weeks
O	693	694	)
O	694	695	.

O	696	699	The
O	700	707	primary
O	708	711	end
O	712	717	point
O	718	721	was
B-outcome-Measure	722	733	development
I-outcome-Measure	734	736	of
I-outcome-Measure	737	740	AIA
O	740	741	.

O	742	745	The
O	746	751	trial
O	752	755	was
O	756	764	designed
O	765	767	to
O	768	774	enroll
B-total-participants	775	778	184
O	779	787	patients
O	787	788	.

O	789	793	This
O	794	802	futility
O	803	811	analysis
O	812	815	was
O	816	825	performed
O	826	831	after
B-total-participants	832	834	93
O	835	843	patients
O	844	848	were
O	849	857	enrolled
O	857	858	.

O	859	862	The
O	863	867	high
O	867	868	-
O	868	872	dose
O	873	880	vitamin
O	881	882	D
O	883	890	regimen
O	891	894	was
O	895	904	effective
O	905	907	in
O	908	915	raising
B-outcome	916	921	serum
I-outcome	922	929	vitamin
I-outcome	930	931	D
I-outcome	932	938	levels
O	938	939	,
O	940	943	but
O	944	949	there
O	950	953	was
O	954	956	no
O	957	968	significant
O	969	979	difference
O	980	982	in
O	983	994	development
O	995	997	of
O	998	1001	AIA
O	1002	1009	between
O	1010	1013	the
O	1014	1017	two
O	1018	1022	arms
O	1022	1023	.

O	1024	1026	In
O	1027	1030	the
O	1031	1035	high
O	1035	1036	-
O	1036	1040	dose
O	1041	1044	arm
O	1044	1045	,
B-iv-bin-abs	1046	1048	25
O	1049	1057	patients
O	1058	1059	(
B-iv-bin-percent	1059	1061	54
I-iv-bin-percent	1061	1062	%
O	1062	1063	)
B-outcome	1064	1073	developed
I-outcome	1074	1077	AIA
O	1077	1078	,
O	1079	1087	compared
O	1088	1090	to
B-cv-bin-abs	1091	1093	27
O	1094	1102	patients
O	1103	1104	(
B-cv-bin-percent	1104	1106	57
I-cv-bin-percent	1106	1107	%
O	1107	1108	)
O	1109	1111	in
O	1112	1115	the
O	1116	1124	standard
O	1124	1125	-
O	1125	1129	dose
O	1130	1133	arm
O	1133	1134	.

O	1135	1138	The
O	1139	1146	planned
O	1147	1155	futility
O	1156	1164	analysis
O	1165	1168	was
O	1169	1177	positive
O	1177	1178	;
O	1179	1183	thus
O	1183	1184	,
O	1185	1188	the
O	1189	1194	study
O	1195	1198	was
O	1199	1209	terminated
O	1209	1210	.

O	1211	1218	Neither
O	1219	1227	baseline
O	1228	1235	vitamin
O	1236	1237	D
O	1238	1241	nor
O	1242	1244	12
O	1244	1245	-
O	1245	1249	week
O	1250	1257	vitamin
O	1258	1259	D
O	1260	1265	level
O	1266	1269	was
O	1270	1280	predictive
O	1281	1283	of
B-outcome	1284	1287	AIA
I-outcome	1288	1299	development
O	1299	1300	.

O	1301	1309	Although
O	1310	1317	vitamin
O	1318	1319	D
O	1320	1326	levels
O	1327	1331	were
O	1332	1341	increased
O	1342	1344	in
O	1345	1348	the
O	1349	1353	high
O	1353	1354	-
O	1354	1358	dose
O	1359	1362	arm
O	1362	1363	,
O	1364	1369	there
O	1370	1373	was
O	1374	1376	no
O	1377	1388	significant
O	1389	1395	signal
O	1396	1399	for
O	1400	1407	benefit
O	1408	1410	of
O	1411	1415	high
O	1415	1416	-
O	1416	1420	dose
O	1421	1428	vitamin
O	1429	1430	D
O	1431	1446	supplementation
O	1447	1450	for
O	1451	1454	AIA
O	1455	1465	prevention
O	1466	1468	in
O	1469	1473	this
O	1474	1483	unblinded
O	1484	1489	trial
O	1489	1490	.

O	1491	1495	This
O	1496	1501	study
O	1501	1502	,
O	1503	1508	along
O	1509	1513	with
O	1514	1521	several
O	1522	1528	others
O	1528	1529	,
O	1530	1537	implies
O	1538	1542	that
O	1543	1550	vitamin
O	1551	1552	D
O	1553	1559	likely
O	1560	1564	does
O	1565	1568	not
O	1569	1573	play
O	1574	1575	a
O	1576	1587	significant
O	1588	1592	role
O	1593	1595	in
O	1596	1599	AIA
O	1600	1603	for
O	1604	1607	the
O	1608	1616	majority
O	1617	1619	of
O	1620	1628	patients
O	1628	1629	.
